Open AccessCML
Author(s) -
Mark Fuerst
Publication year - 2012
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000413199.69599.b9
Subject(s) - dasatinib , nilotinib , imatinib , medicine , discontinuation , myeloid leukemia , oncology , tyrosine kinase , minimal residual disease , disease , hematology , leukemia , receptor